Fiona Murray
Direktor/Vorstandsmitglied bei Celixir Plc
Profil
Fiona Murray is currently a Director at Celixir Plc.
She previously worked as a Non-Executive Director at Cell Therapy Ltd.
Dr. Murray holds a doctorate degree from Harvard University and a graduate degree from the University of Oxford.
Aktive Positionen von Fiona Murray
| Unternehmen | Position | Beginn |
|---|---|---|
Celixir Plc
 Celixir Plc Pharmaceuticals: MajorHealth Technology Celixir Plc discovers and develops regenerative medicines to treat life threatening and life altering diseases. It offers heartcel-immunomodulatory progenitor imp cells, tendoncel-platelet lysate based therapy, myocardion-progenitor cells of mesodermal lineage. The company was founded by Martin Evans and Ajan Reginald in 2009 and is headquartered in Stratford-upon-Avon, the United Kingdom. | Direktor/Vorstandsmitglied | - |
Ehemalige bekannte Positionen von Fiona Murray
| Unternehmen | Position | Ende |
|---|---|---|
Cell Therapy Ltd.
 Cell Therapy Ltd. BiotechnologyHealth Technology Cell Therapy Ltd. produces regenerative medicines using adult stem cells to treat heart failure. Its product HeartCel, a stem cell therapy that offers improved outcomes for heart failure patients by reducing the size of heart scar, improving heart function, quality of life and reducing mortality. The firm develops therapies based on the adult mesenchymal stromal cells technology platform. The firm’s regenerative therapies will focus on curing the cause of the disease, rather than only treating the symptoms. The company was founded in 2009 by Martin John Evans and Ajan Trevor Reginald and is headquartered in Cardiff, the United Kingdom. | Direktor/Vorstandsmitglied | - |
Ausbildung von Fiona Murray
| Harvard University | Doctorate Degree |
| University of Oxford | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
Cell Therapy Ltd.
Cell Therapy Ltd. BiotechnologyHealth Technology Cell Therapy Ltd. produces regenerative medicines using adult stem cells to treat heart failure. Its product HeartCel, a stem cell therapy that offers improved outcomes for heart failure patients by reducing the size of heart scar, improving heart function, quality of life and reducing mortality. The firm develops therapies based on the adult mesenchymal stromal cells technology platform. The firm’s regenerative therapies will focus on curing the cause of the disease, rather than only treating the symptoms. The company was founded in 2009 by Martin John Evans and Ajan Trevor Reginald and is headquartered in Cardiff, the United Kingdom. | Health Technology |
Celixir Plc
Celixir Plc Pharmaceuticals: MajorHealth Technology Celixir Plc discovers and develops regenerative medicines to treat life threatening and life altering diseases. It offers heartcel-immunomodulatory progenitor imp cells, tendoncel-platelet lysate based therapy, myocardion-progenitor cells of mesodermal lineage. The company was founded by Martin Evans and Ajan Reginald in 2009 and is headquartered in Stratford-upon-Avon, the United Kingdom. | Health Technology |